Unravelling the Potential Neuroprotective Facets of Erythropoietin for the Treatment of Alzheimer's Disease

Dapinder Kaur,Tapan Behl,Aayush Sehgal,Sukhbir Singh,Neelam Sharma,Vishnu Nayak Badavath,Syed Shams ul Hassan,Mohammad Mehedi Hasan,Saurabh Bhatia,Ahmed Al-Harassi,Haroon Khan,Simona Bungau
DOI: https://doi.org/10.1007/s11011-021-00820-6
IF: 3.6551
2022-01-01
Metabolic Brain Disease
Abstract:During the last three decades, recombinant DNA technology has produced a wide range of hematopoietic and neurotrophic growth factors, including erythropoietin (EPO), which has emerged as a promising protein drug in the treatment of several diseases. Cumulative studies have recently indicated the neuroprotective role of EPO in preclinical models of acute and chronic neurodegenerative disorders, including Alzheimer's disease (AD). AD is one of the most prevalent neurodegenerative illnesses in the elderly, characterized by the accumulation of extracellular amyloid-ss (Ass) plaques and intracellular neurofibrillary tangles (NFTs), which serve as the disease's two hallmarks. Unfortunately, AD lacks a successful treatment strategy due to its multifaceted and complex pathology. Various clinical studies, both in vitro and in vivo, have been conducted to identify the various mechanisms by which erythropoietin exerts its neuroprotective effects. The results of clinical trials in patients with AD are also promising. Herein, it is summarized and reviews all such studies demonstrating erythropoietin's potential therapeutic benefits as a pleiotropic neuroprotective agent in the treatment of Alzheimer's disease.
What problem does this paper attempt to address?